Advances in engineering heart tissue reported by MIT scienti
SEPTEMBER 28, 1999
CAMBRIDGE, Mass. -- Lisa E. Freed clearly remembers her first successful
experiment in engineering heart tissue: the cells she'd "seeded"
on a three-dimensional scaffold outside a living body began beating as one.
"It was my most awesome laboratory moment ever. No one had ever done
this before," said Dr. Freed, a principal research scientist in the
Harvard-MIT Division of Health Sciences and Technology (HST).
That was five years ago. Since then Dr. Freed, Gordana Vunjak-Novakovic
(her collaborator then and now) and colleagues from MIT, Harvard Medical
School, Boston University, and Brigham and Women's Hospital have been
painstakingly studying the engineered cardiac tissue.
Among other things, they've characterized the tissues' structural and
electrical properties (heart function depends on the ability to conduct
electrical impulses), and they've defined key parameters for growing the
tissues. Two papers published this month and last report their results.
The work is key to engineering 3D cardiac tissue that could eventually be
used to repair damaged heart tissue inside the body, test new drugs, and
study general cardiac tissue development and function. Although it could
theoretically lead to the creation of an entire heart, the researchers
stress that substantial problems must be solved before that could happen.
The MIT approach involves seeding cardiac cells onto a 3D polymer
scaffold that slowly biodegrades as the cells develop into a full tissue.
The researchers have used the same technique to grow other tissues; in 1996
Drs. Freed and Vunjak-Novakovic with NASA colleagues grew cartilage aboard
the Space Station Mir in the first tissue-engineering experiment in space.
The cardiac cells are cultivated on scaffolds five millimeters in
diameter by two thick. The cell/scaffold constructs are placed in a rotating
bioreactor that supplies the cells with nutrients and gases and removes
wastes. "The bioreactor is a kind of microenvironment that gives cells
the signals they would ordinarily see in the body," said Dr.
Vunjak-Novakovic. "This overall system allows us to study specific
effects of the cells, scaffold, and regulatory signals on tissue development
and function," Dr. Freed said.
In the August issue of the American Journal of Physiology, the
researchers characterize the structure and electrical properties of the
cardiac constructs. Using a custom-designed electrode array, they applied
electrical signals to the tissues and got them beating. They then studied
parameters associated with impulse propagation through the tissue. For
example, they found that constructs conducted electrical impulses half as
fast as tissues grown the old-fashioned way (in an animal's body).
A second paper, which appeared in the September 1999 issue of
Biotechnology and Bioengineering, describes how parameters like cell
density, cell source (neonatal rat or chick embryo), and different
cultivation conditions affect tissue growth. "We've identified a set of
conditions that so far appear to be best for cardiac tissue
engineering," Dr. Vunjak-Novakovic said.
Work continues. "There are substantial problems that must be
addressed before we could use these tissues for, say, repair of heart
defects inside the body," Dr. Freed said. For example, the current
constructs resemble heart muscle, but the heart also contains blood vessels.
"We've developed one component, but that is only the first step,"
Dr. Freed said.
In addition, constructs must be bigger, stronger, and made of human
rather than animal cells that have been modified so they will not be
rejected by a recipient. Dr. Freed noted that at least one other group, in
Germany, is also working on cardiac tissue engineering.
The first successful experiment five years ago "showed that cardiac
tissue engineering was possible," Dr. Vunjak-Novakovic said. The
current papers are the first to quantitatively characterize tissue
properties. "They're really the beginning," she concluded.
Authors of the American Journal of Physiology paper are Nenad Bursac, a
Boston University (BU) graduate student and HST visiting scholar; Maria
Papadaki, an HST postdoctoral associate; Richard J. Cohen, Whitaker
Professor of Biomedical Engineering at HST; Frederick J. Schoen, associate
director of HST, a professor at Harvard Medical School, and affiliated with
Brigham and Women's Hospital; Professor Solomon R. Eisenberg, associate dean
of engineering at BU; Rebecca L. Carrier, a graduate student in MIT's
Department of Chemical Engineering (CE); Dr. Vunjak-Novakovic and Dr. Freed.
Authors of the Biotechnology and Bioengineering paper are Ms. Carrier;
Dr. Papadaki; Maria Rupnick of Harvard Medical School, Brigham and Women's
and an MIT CE Research Affiliate; Dr. Schoen; Mr. Bursac; Robert S. Langer,
MIT's Germeshausen Professor of Chemical & Biomedical Engineering; Dr.
Freed and Dr. Vunjak-Novakovic.
The work was supported by NASA.